Your browser doesn't support javascript.
A cross-sectional study of baricitinib outcome in severe COVID-19 pneumonia
Indian Journal of Critical Care Medicine ; 25(SUPPL 1):S6, 2021.
Article in English | EMBASE | ID: covidwho-1200228
ABSTRACT

Introduction:

An inflammatory response to SARS-CoV-2 infection, due to cytokine release syndrome, has been implicated in the pathology of acute respiratory distress syndrome in patients with COVID-19. Baricitinib is a reversible JAK-inhibitor that interrupts the multiple inflammatory cytokines in COVID-19 immunopathology.

Objectives:

Our aim to study the overall outcome of baricitinib on critical patients with COVID-19. Materials and

methods:

A cross-sectional study of 10 cases, infected with COVID-19 severe pneumonia and were critically ill. The patient's average ICU stay, CBC, changes in HRCT scans, clinical improvement, cytokine storm markers before and after baricitinib doses were taken into account. Due consent was taken from all patients.

Results:

Seventy percent of patients showed a reduction in CRP values. In 70% of patients, D-dimer values either decreased or were kept within normal limits. 90% of patients were shifted from NIV support to NRBM within 7 days of baricitinib. 50% of patients showed a rising trend in platelet counts. 70% patients were shifted to ward from ICU 30% patients were discharged within 7 days of Baricitinib. Discussions Baricitinib is the Janus kinase (JAK) inhibitor, which may prevent cytokine storm in patients with SARS-CoV-2 pneumonia.

Conclusion:

In our study, baricitinib has shown promising results. It is incumbent on researchers to develop and validate reliable tools to monitor the overall outcome of patients with baricitinib in COVID-19.

Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Indian Journal of Critical Care Medicine Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Indian Journal of Critical Care Medicine Year: 2021 Document Type: Article